Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male wistar rats

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 4, 2003, Pages 173-181

  Bittner, Beate ^a   González, Roberto Carlos Bravo ^a   Walter, Isabelle ^a   Kapps, Martin ^a   Huwyler, Jörg ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Colchicine; Hepatocytes; Pharmacokinetics; Rat; Solutol HS 15

Indexed keywords

COLCHICINE; SODIUM CHLORIDE; SOLUTOL HS 15; SURFACTANT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERYTHROCYTE LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TRANSPORT; DRUG URINE LEVEL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL; MALE; NONHUMAN; RAT; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY;

ANIMALS; COLCHICINE; CYTOCHROME P-450 ENZYME SYSTEM; EXCIPIENTS; HEPATOCYTES; INJECTIONS, INTRAVENOUS; MALE; P-GLYCOPROTEIN; POLYETHYLENE GLYCOLS; PROTEIN BINDING; RATS; RATS, WISTAR; STEARIC ACIDS;

EID: 0037687293     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.353     Document Type: Article

References (37)

1. Bittner B, Mountfield RJ. Intravenous administration of poorly soluble new drug entities in early drug discivery: The potential impact of formulation on pharmacokinetic parameters. Curr Opin Drug Disc Dev 2002; 5: 59-71.
2. Ruchatz F, Schuch H. Physicochemical properties of Solutol HS 15 and its solubisates. BASF ExAct 1998; 1: 6-7.
3. Coon JS, Knudson W, Clodfelter K, Lu B, Weinstein RS. Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance. Cancer Res 1991; 51: 897-902.
4. Chong ASF, Markham PN, Gebel HM, Bines SD, Coon JS. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 1993; 36: 133-139.
5. Buckingham LE, Balasubramanian M, Emanuele RM, Clodfelter KE, Coon JS. Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents. Int J Cancer 1995; 62: 436-442.
6. Bravo González RC, Mountfield RJ, Walter I, Delobel F, Bittner B. Impact of Solutol HS 15 on the clearance of midazolam in rat hepatocytes. Drug Metab Rev 2001; 33: 183.
7. Van Zuylen L, Karlsson MO, Verweij J et al. Pharmacokinetic modeling of paclitaxel encapsulation in cremophor EL micelles. Cancer Chemother Pharmacol 2001; 47: 309-318.
8. Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001; 19: 125-141.
9. Bittner B, Fullhardt P, Zuercher G, Bravo Gonzaléz RC, Mountfield RJ. Improvement of the oral bioavailability of colchicine in rats by co-administration of D-α-tocopherol polyethylene glycol 1000 succinate and polyethoxylated derivative of 12-hydroxy-stearic acid. Arznein Forsch/Drug Res 2002; 52: 684-688.
10. Roberts WN, Liang MH, Stern SH. Colchicine in acute gout. Reassessment of risks and benefits. J Am Med Assoc 1987; 257: 1920-1922.
11. Levy M, Eliakim M. Long-term colchicine prophylaxis in familial Mediterranean fever. Br Med J 1977; 2: 808.
12. Kershenobich D, Uribe N, Suarez GI, Mata JM, Perez-Tamayo R, Rojkind R. Treatment of cirrhosis with colchicine: a double-blind, randomized trial. Gastroenterology 1979; 77: 532-536.
13. Kershenobich D, Vargas F, Garcia-Tsao G, Perez-Tamayo R, Gent M, Rojkind R. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988; 318: 1709-1713.
14. Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L. A controlled trial of colchicine in primary biliary cirrhosis: trial design and preliminary report. J Hepatol 1987; 5: 1-7.
15. Sabouraud A, Rochdi M, Urtizberea M, Christen MO, Achtert G, Scherrmann JM. Pharmacokinetics of colchicine: A review of experimental and clinical data. Z Gastroenterol 1992; 30: 35-39.
16. Race TF, Paes IC, Faloon WW. Intestinal malabsorption induced by oral colchicine. Am J Med Sci 1970; 259: 32-41.
17. Leighton JA, Bay MK, Maldonado AL, Johnson RF, Schenker S. The effect of liver dysfunction on colchicine pharmacokinetics in rat. Hepatology 1990; 11: 210-215.
18. Desrayaud S, Guntz P, Scherrmann JM, Lemaire M. Effect of the p-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci 1997; 61: 153-163.
19. Tateishi T, Soucek P. Caraco Y, Guengerich P, Wood AJJ. Colchicine biotransformation by human liver microsomes. Biochem Pharmacol 1997; 53: 111-116.
20. Walaszek EJ, Kocsis JJ, Leroy GV, Geiling EMK. Studies on the excretion of radioactive colchicine. Arch Int Pharmacodyn 1960; 125: 371-382.
21. Girre C, Thomas G, Scherrmann JM, Crouzette J, Fournier PE. Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers. Fundam Clin Pharmacol 1989; 3: 537-543.
22. Lavé T, Dupin S, Schmitt C, Valles B, Ubaud G, Chou RC. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 1997; 14: 152-155.
23. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976; 13: 29-83.
24. Ubeaud G, Schmitt C, Jaeck D, Lavé T, Coassolo P. Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 1995; 25: 1381-1390.
25. Wilkins JN, Ashofteh A, Setoda D, Wheatley WS, Huigen H, Ling W. Ultrafiltration using the Amicon MPS-1 for assessing methadone plasma protein binding. Ther Drug Monit 1997; 19: 83-87.
26. Schönharting M, Mende G, Siebert G. The metabolism of colchicine by mammalian liver microsomes. Hoppe-Seyler's Z Physiol Chem 1974; 355: 1391-1399.
27. Bravo González RC, Mountfield RJ, Fullhardt P, Huwyler J, Bittner B. In vitro characterization of an emulsion preconcentrate formulation designed for the oral administration of poorly soluble compounds. Proc Symp Control Rel Bioact Mater 2001; 28: 350.
28. Besarab A, Jarrell BE, Hirsch S, Carabasi RA, Cressman MD, Green P. Use of the isolated perfused kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, cremophor EL. Transplantation 1987; 44: 195-201.
29. Speeg KV, Maldonado, AL, Liaci, J, Muirhead D. Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo. J Pharmacol Exp Ther 1992; 261: 50-55.
30. Sakaeda T, Hirano K. O/W lipid emulsions for parenteral drug delivery II. Effect of composition on pharmacokinetics of incorporated drug. J Drug Targ 1995; 3: 221-230.
31. Buszello K, Harnisch S, Müller RH, Müller BW. The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with Solutol HS 15. Eur J Pharm Biopharm 2000; 49: 143-149.
32. Tanigawara Y. Role of p-glycoprotein in drug disposition. Ther Drug Monit 2000; 22: 137-140.
33. Boekhorst PA, van Kapel J, Schoester M, Sonneveld P. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother Pharmacol 1992; 30: 238-242.
34. Drewe J, Gutmann H, Fricker G, Török M, Beglinger C, Huwyler J. HIV protease inhibitor ritonavir: a more potent inhibitor of p-glycoprotein than the cyclosporine analog SDZ 833. Biochem Pharmacol 1999; 57: 1147-1152.
35. Orlowski S, Selosse MA, Boudon C et al. Effects of detergents on p-glycoprotein ATPase activity: differences in perturbations of basal and verapamil-dependent activities. Cancer Biochem Biophys 1998; 16: 85-110.
36. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of p-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 1992; 267: 24995-25002.
37. Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS. Reversal of multidrug resistance phenotype by surfactants: Relationship to membrane lipid fluidity. Arch Biochem Biophys 1995; 319: 309-315.